Metastatic HR+ Breast Cancer

Authored by Open Medicine, published on 2026-05-27 23:06:18.0

Biomarker-driven treatment pathway for advanced HR-positive/HER2-negative metastatic breast cancer, prioritizing endocrine therapy with CDK4/6 inhibition and adapting based on timing of relapse and molecular alterations. Subsequent therapy selection is guided by actionable mutations (e.g., ESR1, PIK3CA, AKT/PTEN, BRCA), enabling targeted treatments such as SERDs, PI3K/AKT inhibitors, and PARP inhibitors.

  1. Advanced / Metastatic HR-positive/HER2-negative Breast Cancer confirmed
    Current guidelines support reassessment of ER/PR/HER2 on metastatic tissue when feasible and use of actionable biomarkers including PIK3CA, ESR1, BRCA1/2, and HER2-low/ultralow status in treatment planning.
    • ET (recurrence ≤12 mos of adj ET)
      Recurrence during adjuvant endocrine therapy or within 12 months of completion is a standard endocrine-resistant scenario and is the exact population used for inavolisib-based registration.
      • PIK3CA Mut+ Inavolisib + Palbo + Fulvestrant
        This regimen is FDA approved and supported by phase III INAVO120 for PIK3CA-mutant, HR-positive/HER2-negative advanced disease recurring on or after adjuvant endocrine therapy and without prior systemic therapy for advanced disease.
        • ESR1 mutation
          Acquired ESR1 mutation predicts relative resistance to further AI-based therapy and identifies patients for oral ER-targeting agents. Plasma ctDNA testing is widely used in practice.
          • Elacestrant / Imlunestrant
            Elacestrant is supported by phase III EMERALD and is established in ESR1-mutated disease after prior ET plus CDK4/6 inhibitor. Imlunestrant became FDA approved in 2025 for ESR1-mutated ER-positive/HER2-negative advanced disease after at least one line of endocrine therapy.
            • T-DXd (HER2 IHC ultra-low/low)
              DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
            • Chemo
              Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
              • Dato-DXd (post chemo)
                FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
            • At least 2 prior lines of systemic rx
              • Sacituzumab govitecan
                TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
        • PIK3CA mutation
          PIK3CA mutation supports PI3K-pathway targeting. It is relevant both for alpelisib-based therapy after endocrine progression and for inavolisib in the earlier, narrowly defined endocrine-resistant first metastatic-line setting.
          • Alpelisib + Fulvestrant
            SOLAR-1 established efficacy in PIK3CA-mutated disease and regulatory approval remains current; toxicity management is central to real-world use.
            • Chemo
              Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
              • Dato-DXd (post chemo)
                FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
            • T-DXd (HER2 IHC ultra-low/low)
              DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
            • At least 2 prior lines of systemic rx
              • Sacituzumab govitecan
                TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
        • PIK3CA / AKT1 / PTEN alteration
          CAPItello-291 and FDA labeling define PIK3CA, AKT1, or PTEN alteration as the key biomarker group for capivasertib plus fulvestrant.
          • Capivasertib + Fulvestrant
            CAPItello-291 is a phase III practice-changing trial and FDA approval directly matches this biomarker-selected setting.
            • T-DXd (HER2 IHC ultra-low/low)
              DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
            • Chemo
              Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
              • Dato-DXd (post chemo)
                FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
            • At least 2 prior lines of systemic rx
              • Sacituzumab govitecan
                TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
        • gBRCA mutation
          Pathogenic germline BRCA1/2 mutation supports use of olaparib or talazoparib in HER2-negative metastatic breast cancer, generally after appropriate endocrine use in HR-positive disease or when endocrine therapy is no longer appropriate.
          • PARPi
            Olaparib and talazoparib are supported by pivotal randomized trials and remain guideline-concordant targeted alternatives to chemotherapy.
            • Chemo
              Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
              • Dato-DXd (post chemo)
                FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
            • T-DXd (HER2 IHC ultra-low/low)
              DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
            • At least 2 prior lines of systemic rx
              • Sacituzumab govitecan
                TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
        • Everolimus + Exemestane OR Fulvestrant-based Therapy +/- CDK4/6 Inhibitor
          BOLERO-2 firmly supports everolimus-exemestane after prior AI exposure. For post-CDK4/6 continuation/switch, evidence exists for selected regimens such as abemaciclib-fulvestrant and ribociclib with endocrine switch, but this remains less standardized than biomarker-directed branches.
          • T-DXd (HER2 IHC ultra-low/low)
            DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
          • Chemo
            Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
            • Dato-DXd (post chemo)
              FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
          • At least 2 prior lines of systemic rx
            • Sacituzumab govitecan
              TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
    • Endocrine Therapy + Abemaciclib OR Ribociclib
      Major guidelines continue to favor endocrine therapy plus a CDK4/6 inhibitor first line in endocrine-sensitive disease. Ribociclib has the most consistent mature OS evidence; abemaciclib is also guideline-concordant with durable efficacy.
      • ESR1 mutation
        Acquired ESR1 mutation predicts relative resistance to further AI-based therapy and identifies patients for oral ER-targeting agents. Plasma ctDNA testing is widely used in practice.
        • Elacestrant / Imlunestrant
          Elacestrant is supported by phase III EMERALD and is established in ESR1-mutated disease after prior ET plus CDK4/6 inhibitor. Imlunestrant became FDA approved in 2025 for ESR1-mutated ER-positive/HER2-negative advanced disease after at least one line of endocrine therapy.
          • T-DXd (HER2 IHC ultra-low/low)
            DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
          • Chemo
            Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
            • Dato-DXd (post chemo)
              FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
          • At least 2 prior lines of systemic rx
            • Sacituzumab govitecan
              TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
      • PIK3CA mutation
        PIK3CA mutation supports PI3K-pathway targeting. It is relevant both for alpelisib-based therapy after endocrine progression and for inavolisib in the earlier, narrowly defined endocrine-resistant first metastatic-line setting.
        • Alpelisib + Fulvestrant
          SOLAR-1 established efficacy in PIK3CA-mutated disease and regulatory approval remains current; toxicity management is central to real-world use.
          • Chemo
            Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
            • Dato-DXd (post chemo)
              FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
          • T-DXd (HER2 IHC ultra-low/low)
            DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
          • At least 2 prior lines of systemic rx
            • Sacituzumab govitecan
              TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
      • PIK3CA / AKT1 / PTEN alteration
        CAPItello-291 and FDA labeling define PIK3CA, AKT1, or PTEN alteration as the key biomarker group for capivasertib plus fulvestrant.
        • Capivasertib + Fulvestrant
          CAPItello-291 is a phase III practice-changing trial and FDA approval directly matches this biomarker-selected setting.
          • T-DXd (HER2 IHC ultra-low/low)
            DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
          • Chemo
            Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
            • Dato-DXd (post chemo)
              FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
          • At least 2 prior lines of systemic rx
            • Sacituzumab govitecan
              TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
      • gBRCA mutation
        Pathogenic germline BRCA1/2 mutation supports use of olaparib or talazoparib in HER2-negative metastatic breast cancer, generally after appropriate endocrine use in HR-positive disease or when endocrine therapy is no longer appropriate.
        • PARPi
          Olaparib and talazoparib are supported by pivotal randomized trials and remain guideline-concordant targeted alternatives to chemotherapy.
          • Chemo
            Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
            • Dato-DXd (post chemo)
              FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
          • T-DXd (HER2 IHC ultra-low/low)
            DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
          • At least 2 prior lines of systemic rx
            • Sacituzumab govitecan
              TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
      • Everolimus + Exemestane OR Fulvestrant-based Therapy +/- CDK4/6 Inhibitor
        BOLERO-2 firmly supports everolimus-exemestane after prior AI exposure. For post-CDK4/6 continuation/switch, evidence exists for selected regimens such as abemaciclib-fulvestrant and ribociclib with endocrine switch, but this remains less standardized than biomarker-directed branches.
        • T-DXd (HER2 IHC ultra-low/low)
          DESTINY-Breast06 and FDA approval moved trastuzumab deruxtecan earlier for HR-positive HER2-low/HER2-ultralow disease after progression on endocrine therapy in the metastatic setting.
        • Chemo
          Guidelines continue to support single-agent chemotherapy in later lines and in patients no longer suited to endocrine-based strategies.
          • Dato-DXd (post chemo)
            FDA approval is specific to prior endocrine-based therapy and chemotherapy for unresectable/metastatic disease. TROPION-Breast01 supports PFS benefit versus chemotherapy, but OS was not statistically significant in final analysis.
        • At least 2 prior lines of systemic rx
          • Sacituzumab govitecan
            TROPiCS-02 showed benefit over physician’s-choice chemotherapy, and FDA labeling specifies endocrine-based therapy plus at least two additional systemic therapies in the metastatic setting.
tosprivacyYouTube: Metastatic Hormone Receptor Positive (HR+) Breast Cancer Treatment Algorithm: Dr. Kevin KalinskyNCCN Breast Cancer 1L guidelinesA Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)FDA approves inavolisib with palbociclib and fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancerINAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerAbemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR-positive, HER2-negative advanced breast cancer: final overall survival results of MONARCH 3FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancerElacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD TrialAlpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer (SOLAR-1)FDA approves alpelisib for metastatic breast cancerFDA approves capivasertib with fulvestrant for breast cancerCapivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyCapivasertib in Hormone Receptor-Positive Advanced Breast Cancer (CAPItello-291)FDA approves olaparib for germline BRCA-mutated metastatic breast cancerFDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancerOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (OlympiAD)Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation (EMBRACA)FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancerEMERALD: Pivotal trial in ESR1-mutated, ER+/HER2- mBC patients with 100% prior ET + CDK4/6i exposure and prior chemotherapy permittedEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerEverolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2)Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancerPatient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trialFDA approves sacituzumab govitecan-hziy for HR-positive breast cancerOverall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trialFDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer